Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.…
Does Parabilis Medicines (PBLS) Have the Potential to Rally 44.11% as Wall Street Analysts Expect?
Parabilis Medicines (NASDAQ: PBLS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 145 employees.
The shares were at 27.44 USD on 20 November 2026. Its 52-week range is 22.66 USD to 42.34 USD: the price is 35.2% below the high and 21.1% above the low.
Its market capitalisation is 3.44B USD.
It holds more cash than debt, a net cash position of 829.80M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 6 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 41.00 USD is 49.4% above the current price. The next earnings report is expected on 18 March 2027.